Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin.
about
Pathogenesis of Helicobacter pylori infectionSecond and third line treatment options for Helicobacter pylori eradicationCYP2C19 polymorphism influences Helicobacter pylori eradicationThe Importance of Patient-Specific Factors for Hepatic Drug Response and ToxicityTreatment of Helicobacter pylori infection: current status and future concepts.Associations between cytokine gene polymorphisms and susceptibility to Helicobacter pylori infection and Helicobacter pylori related gastric cancer, peptic ulcer disease: A meta-analysisChanges in 12-Year First-Line Eradication Rate of Helicobacter pylori Based on Triple Therapy with Proton Pump Inhibitor, Amoxicillin and Clarithromycin.Clinical application of pharmacogenomics.Responsiveness to low-dose warfarin associated with genetic variants of VKORC1, CYP2C9, CYP2C19, and CYP4F2 in an Indonesian population.Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy.Treatment of Helicobacter pylori infection: Past, present and futurePharmacogenetics of the proton pump inhibitors: a systematic review.Review article: treatment of Helicobacter pylori infection and factors influencing eradication.CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor.Impact of PSCA variation on gastric ulcer susceptibility.Ethical perspectives on pharmacogenomic profiling in the drug development process.Rifabutin-based high-dose proton-pump inhibitor and amoxicillin triple regimen as the rescue treatment for Helicobacter pyloriSofalcone, a mucoprotective agent, increases the cure rate of Helicobacter pylori infection when combined with rabeprazole, amoxicillin and clarithromycin.Virulence factor genotypes of Helicobacter pylori affect cure rates of eradication therapy.Influence of inflammatory cytokine polymorphisms on eradication rates of Helicobacter pylori.Appropriate first-line regimens to combat Helicobacter pylori antibiotic resistance: an Asian perspective.Effectiveness of three times daily lansoprazole/amoxicillin dual therapy for Helicobacter pylori infection in Korea.Pharmacogenomics of proton pump inhibitors.Effect of bacterial and host factors on Helicobacter pylori eradication therapyGenetic polymorphisms of cytochrome P450 enzymes and the effect on interindividual, pharmacokinetic variability in extensive metabolizers.Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypesEffects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes.Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status.CYP2C19 polymorphism and proton pump inhibitors.HIV-Helicobacter pylori Co-Infection: Antibiotic Resistance, Prevalence, and Risk Factors.PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19.Pharmacogenetics-based new therapeutic concepts.Efficacy of esomeprazole in treating acid-related diseases in Japanese populationsMolecular biology methods for the characterization of Helicobacter pylori infections and their diagnosis.CYP2C19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteersRole of cytochrome P450 genotype in the steps toward personalized drug therapy.The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis.Treatment strategy to eradicate Helicobacter pylori infection: impact of pharmacogenomics-based acid inhibition regimen and alternative antibiotics.High Dose Ilaprazole/Amoxicillin as First-Line Regimen for Helicobacter pylori Infection in Korea.Population pharmacokinetics of omeprazole in a random Iranian population.
P2860
Q24679810-81FF1D35-E942-49F8-95FA-98519D05110AQ26829666-31879990-AF76-41C7-B106-D7688513AA7EQ27005916-EF0A45C3-2CD2-417D-A809-2261DCB54F30Q28080256-6A7F248C-4D25-4AA7-9752-68C34C7257D0Q33594850-7FECE41C-BE6C-4614-A981-61704D3BA48DQ33615027-18DC5AE3-513F-4FFA-9A51-5D435CE5B0A6Q33983562-BB57C938-51FE-41DB-89DE-1DF967BCAD6AQ34280685-243EF48F-D17E-4541-94C2-2E0B118B5E09Q34362277-A40A84E2-D28A-4922-8F05-D64F5B3A3982Q34368342-64B33C4B-76E4-4EE8-B6E3-667A5A5B733FQ34508830-3C580E44-E6CE-4398-B9FF-9E4003CEBC91Q34532600-23259E19-7A7D-41DC-8D9C-A779549BB1F5Q34534317-37191EE3-C9EE-471A-A756-1EA4C7F4AE3FQ34583603-DCBB6DCF-5CA3-454E-8BD1-A5FE82AE752FQ34737613-3B83ECDD-6CDD-4A65-9ACB-0C03962A5E86Q34743306-0153A5A9-453F-4AA1-935E-CEF7F7B65839Q34823645-A6762953-DE96-4FB1-A8B0-44934710A606Q35011360-054530DA-DDBC-401D-9261-338DE4F2A419Q35056670-687E0433-880E-49CF-A862-0EFBF32F6D8FQ35082607-BD3518F2-C2BB-4034-AEBC-0F4405C527EEQ35598058-5B1EAF8A-F5E6-4528-9E3C-B245DC7F7CF9Q35640492-72607BA8-7BF2-4C4B-B56F-9E8D51D4D556Q35689146-B0C7ACE9-B0FB-4055-951A-0E1C4ACF6B41Q35738262-2D424741-349A-48BE-B9EA-633EFC94FF93Q35753607-41AD670B-CA6B-49E8-BBA1-7B2B322E6C57Q35826075-B6FF7B5C-6782-4DE5-AB60-26A934D91828Q35826832-CB62E5CD-44A3-4481-AE49-0293EB7E6FE0Q35827487-BECDF8DD-6938-47F1-8C80-CA4432BD6ABFQ35831792-D9AF478D-7ECB-47D3-AA0C-9DBEAFA102E4Q35874693-3AC1E7F1-F7FB-4378-B340-C85A80A5302FQ35952367-BD372D77-A76C-461F-8062-233C3959A693Q35956177-24D2E628-8058-47F3-95A6-EC73B73F9FCDQ35987201-E66FFE22-2E69-42C4-9C5A-E92D60889442Q36028541-C72F6BED-CE3E-40EF-AC1F-3F118E6C4966Q36164941-089A73F7-6096-4B84-B475-F68329859379Q36441521-0D18CF36-44B5-4ED3-B9FF-E9C3E418A4AAQ36545135-C8869BA4-4D92-4E28-A0E1-619DCDA140E5Q36979297-066619C9-D20F-44C1-AF6C-F78CB8386DA2Q37060060-5F6C70AC-F737-4C9D-8C66-386DFA06B55CQ37128495-E0092F18-BAA9-4443-8FF8-7DE873EAC89A
P2860
Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Effect of genotypic difference ...... oxicillin, and clarithromycin.
@ast
Effect of genotypic difference ...... oxicillin, and clarithromycin.
@en
type
label
Effect of genotypic difference ...... oxicillin, and clarithromycin.
@ast
Effect of genotypic difference ...... oxicillin, and clarithromycin.
@en
prefLabel
Effect of genotypic difference ...... oxicillin, and clarithromycin.
@ast
Effect of genotypic difference ...... oxicillin, and clarithromycin.
@en
P2093
P356
P1476
Effect of genotypic difference ...... oxicillin, and clarithromycin.
@en
P2093
H Sugimura
M Takashima
T Ishizaki
P304
P356
10.1067/MCP.2001.113959
P407
P577
2001-03-01T00:00:00Z